Celerion talks about research sector in South America

By Gareth Macdonald

- Last updated on GMT

Related tags: Medicine, Brazil, South america

US CRO Celerion gained Brazilian National Health Surveillance Agency (Agência Nacional de Vigilancia Sanitaria ANVISA) approval for its bioanalysis labs in Lincoln, Nebraska and in Belfast, Northern Ireland.

Celerion’s VP of clinical research Phil Bach spoke with Outsourcing-pharma.com at DIA 2011, explaining that demand from several pharma industry customers was the key driver for its efforts to gain Brazilian approval.

Bach said that Brazil’s drug market is going to be worth around $11bn by 2015 and added that this, coupled with the country’s economic stability and improving healthcare infrastructure, Is attractive to pharma companies.

Related news

Show more

Related products

show more

Validating The Simoa Technology

Validating The Simoa Technology

Frontage Laboratories | 01-Oct-2019 | Technical / White Paper

Frontage is the first and only laboratory to validate Quanterix’ Simoa HD1 Analyzer for performing immunoassays. Most of the advanced instruments used...

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us


View more